Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

• M. Hidalgo ^[1] ; A. Carmona ^[2] ; R. Álvarez ^[3] ; J. Gallego ^[4] ; B. Laquente ^[5] ; T. Macarulla ^[6] ; A. Muñoz ^[7] ; M. Salgado ^[8] ; R. Vera ^[9] ; J. Adeva ^[10] ; C. Guillén-Ponce ^[11] ; J. Blázquez ^[12] ; S. Arévalo ^[13] ; A. Calsina ^[14] ; I. Ales ^[15]
  1. [1] Spanish National Cancer CentreMadridSpain
  2. [2] University Hospital Morales MesseguerMurciaSpain
  3. [3] Centro Integral Oncológico Clara CampalMadridSpain
  4. [4] University Hospital of ElcheElcheSpain
  5. [5] Institut Català d´OncologiaBarcelonaSpain
  6. [6] Vall d’Hebrón University HospitalBarcelonaSpain
  7. [7] University Hospital Gregorio MarañónMadridSpain
  8. [8] University Hospital of OurenseOurenseSpain
  9. [9] Complejo Hospitalario de NavarraPamplonaSpain
  10. [10] University Hospital 12 de OctubreMadridSpain
  11. [11] Hospital Universitario Ramón y CajalMadridSpain
  12. [12] University Hospital Ramón y CajalMadridSpain
  13. [13] University Hospital DonostiaSan SebastiánSpain
  14. [14] Hospital Germans Trias I PujolInstitut Catalá d´OncologiaBadalonaSpain
  15. [15] Hospital Carlos HayaMálagaSpain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 6, 2017, págs. 667-681
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The management of patients with pancreatic cancer has advanced over the last few years. We convey a multidisciplinary group of experts in an attempt to stablish practical guidelines for the diagnoses, staging and management of these patients. This paper summarizes the main conclusions of the working group. Patients with suspected pancreatic ductal adenocarcinoma should be rapidly evaluated and referred to high-volume centers. Multidisciplinary supervision is critical for proper diagnoses, staging and to frame a treatment plan. Surgical resection together with chemotherapy offers the highest chance for cure in early stage disease. Patients with advanced disease should be classified in treatment groups to guide systemic treatment. New chemotherapeutic regimens have resulted in improved survival. Symptomatic management is critical in this disease. Enrollment in a clinical trial is, in general, recommended.